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Rationale and design of the PeriOperative ISchemic
Evaluation-2 (POISE-2) trial: An international 2 × 2
factorial randomized controlled trial of acetyl-salicylic
acid vs placebo and clonidine vs placebo in patients
undergoing noncardiac surgery
Philip J. Devereaux aBackground Worldwide, 200million adults undergomajor noncardiac surgery annually, and10million of these patientswill
have a major vascular complication. Low-dose clonidine and low-dose acetyl-salicylic acid (ASA) may prevent major perioperative
vascular complications. We therefore initiated the POISE-2 trial to establish the perioperative effects of these 2 interventions.
Methods The POISE-2 trial is a 2 × 2 factorial randomized controlled trial of low-dose ASA vs placebo and low-dose
clonidine vs placebo in 10,000 patients at risk for a perioperative cardiovascular event who are undergoing noncardiac
surgery. Both study drugs are initiated prior to surgery (goal 2-4 hours) and are continued after surgery. Patients, health care
providers, data collectors, and outcome adjudicators are blinded to treatment allocation. The primary outcome is a composite
of mortality and nonfatal myocardial infarction at 30 days after randomization.
Results To date, the POISE-2 trial has recruited more than 9,000 patients from 135 centers in 23 countries. Among the
first 7,500 patients recruited, patients' mean age was 68.2 years, 53.4% were male, 34.0% had a history of vascular
disease, and 38.3% had diabetes that was treated. Participants had orthopedic (38.1%), general (27.0%), urologic or
gynecologic (17.2%), vascular (6.6%), thoracic (5.7%), and other (5.4%) surgery.
Conclusions POISE-2 is a large international trial that will rigorously evaluate the effects of low-dose clonidine and ASA
in patients having noncardiac surgery. (Am Heart J 2014;167:804-809.e4.)Globally, more than 200 million adults have major
noncardiac surgery annually,1 and 10 million of these
patients have a major vascular complication within 30
days of surgery.2,3 Despite the magnitude of this problem,
there is no proven effective and safe intervention to
prevent major perioperative vascular complications.3
Myocardial infarction is the most common major
perioperative vascular complication. In the placebo group
of the POISE trial (a 8,351-patient international periopera-
tive β-blocker trial),4 1.4% of the patients had a vascular
death, 0.5% had a stroke, 0.5% had a nonfatal cardiac arrest,On behalf of The POISE-2 Investigators.
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hand 5.7%had amyocardial infarction in the first 30 days after
surgery.5 Perioperative myocardial infarction portends a
poor prognosis. In POISE, 11.6% of patients with a
perioperative myocardial infarction died within the first
30 days compared with only 2.2% of patients who did not
have a myocardial infarction.5 There remains uncertainty
regarding the pathophysiology of perioperative myocardial
infarction; however, it is likely that both supply-demand
mismatch and coronary thrombus account for a portion of
themyocardial infarctions that occur in the first 30days after
noncardiac surgery.3 A perioperative prevention strategy
would ideally impact both proposed mechanisms to
provide the greatest potential for benefit.
During surgery and in the next few days thereafter, there
is marked activation of the sympathetic system.6,7 Cloni-
dine, an α-2 agonist, blunts central sympathetic outflow
andhas other effects (eg, analgesic, anxiolytic, antishivering,
anti-inflammatory) that may prevent perioperative vascular
complications.8–12 Randomized controlled trials (RCTs)
demonstrate that low-dose perioperative clonidine reduces
myocardial ischemia without inducing hemodynamic insta-
bility13 and suggest that clonidine may prevent death and
myocardial infarction.14
Table I. Inclusion criteria of the POISE-2 trial
ll patients undergoing noncardiac surgery are eligible if they:
1. are ≥45 y of age;
2. are expected to require at least an overnight hospital admission
after surgery; and
3. fulfill any 1 of the following 5 criteria:
A. history of coronary artery disease;
B. history of peripheral arterial disease;
C. history of stroke;
D. undergoing major vascular surgery;
E. any 3 of 9 risk criteria;
i. age ≥70 y;
ii. undergoing major surgery defined as intraperitoneal,
intrathoracic, retroperitoneal, or major orthopedic surgery;
iii. history of congestive heart failure;
iv. history of transient ischemic attack;
v. diabetes and currently taking an oral hypoglycemic agent or insulin;
vi. history of hypertension;
vii. preoperative serum creatinine N175 μmol/L (N2.0 mg/dL);
viii. smokingwithin 2 y of surgery; or undergoing emergent/urgent surgery.
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al of chronic acetyl-salicylic acid (ASA) may result in a
prothrombotic state (ie, increased thromboxane A2 and
decreased fibrinolysis).16,17 Given thesephysiological changes,
ASA initiation or, for chronicusers, ASAcontinuation—and the
associated inhibition of platelet aggregation—may prevent
major perioperative vascular events through impeding throm-
bus formation.18 Large RCTs have demonstrated that ASA
prevents vascular events in the nonoperative setting.19
Although perioperative RCTs suggest that ASA may prevent
vascular death,20 the effect of ASA on myocardial infarction is
unclear,21 and there are concerns that the increased risk of
bleeding may outweigh the benefits.22,23 This uncertainty has
led to great variability in clinical practice.24
We initiated the POISE-2 trial to determine the impact
of low-dose ASA and low-dose clonidine on the 30-day
risk of mortality and nonfatal myocardial infarction in
patients having noncardiac surgery.
Methods
Trial design
POISE-2 is an international RCT of 10,000 patients with,
or at risk for, atherosclerotic disease who are undergoing
noncardiac surgery. Using a 2 × 2 factorial design, POISE-2
will determine the effect of low-dose clonidine vs placebo
and low-dose ASA vs placebo in the perioperative setting.
Patients, health care providers, data collectors, and
outcome adjudicators are blinded to treatment allocation.
Trial population
Study personnel consider patients undergoing elective
and urgent/emergent noncardiac surgery for enrollment.
Tables I and II report the POISE-2 inclusion and exclusion
criteria, respectively. We enroll patients in 1 of 2 ASA
strata. The ASA Continuation Stratum involves patients
who are taking ASA chronically. The ASA Starting Stratum
involves patients who are not taking ASA chronically. We
consider patients who report having taken ASA daily for
at least 1 month within a 6-week period prior to surgery
to be on ASA chronically, and we enroll these patients in
the ASA Continuation Stratum.
Randomization
Randomization occurs prior to surgery for all eligible
patients for whom written informed consent is obtained.
Research personnel randomize patients via a 24-hour
computerized randomization telephone service or interac-
tive Web randomization system maintained by the coordi-
nating center at the Population Health Research Institute a
part of the Hamilton Health Sciences and McMaster
University, Hamilton, Ontario, Canada. The randomization
process uses block randomization stratified by center and
ASA stratum; block size is undisclosed to research
personnel. We randomize patients in a 1:1:1:1 allocation
to receive clonidine/ASA, clonidine/ASA placebo, clonidineAplacebo/ASA, or clonidine placebo/ASA placebo. Patients in
the ASA Continuation Stratum and ASA Starting Stratum are
evenly assigned to each of the 4 randomization groups.
Trial drug administration
Prior to surgery (goal 2-4 hours), patients fulfilling
hemodynamic requirements (ie, systolic blood pressure
≥105 mm Hg and a heart rate ≥55 beats/min) receive 0.2
mg of oral clonidine or matching placebo and have a
transdermal clonidine (0.2 mg/d) or placebo patch applied
to their upper arm or chest. The clonidine patch releases
clonidine at a constant rate (0.2 mg/d), and the patch is
removed at 72 hours after surgery. No cases of clonidine
withdrawal hypertension have been reported with trans-
dermal clonidine25; therefore, we do not use a tapering
process. Research personnel telephone patients discharged
before 72 hours after surgery to remind them to remove the
patch at 72 hours after surgery.
Patients in both ASA strata receive the same trial ASA
intervention (ie, either ASA 100 mg or matching
placebo). For the first dose prior to surgery (goal 2-4
hours), they take 2 tablets orally. Starting on the day
after surgery, patients take 1 tablet daily for 30 days in
the Starting Stratum and 7 days in the Continuation
Stratum, after which they resume their regular ASA.
Monitoring for and approach to potential problems
Patients have monitoring of blood pressure and heart rate
prior to study drug administration, 1 hour after administra-
tion, and every 4 hours for the first 96 hours after surgery.
Decisions regarding holding or discontinuing either study
drug rest with the attending physician. For patients
developing clinically important hypotension or bradycardia,
study personnel encourage the attending physician to
consider fluid resuscitation, administering an inotrope or
vasopressor, withholding nonstudy antihypertensive medi-
cation(s), or changing epidural prescriptions or infusion
Table II. Exclusion criteria of the POISE-2 trial
We will exclude patients meeting any of the following criteria:
1. consumption of ASA within 72 h prior to surgery;
2. hypersensitivity or known allergy to ASA or clonidine;
3. systolic blood pressure b105 mm Hg;
4. heart rate b55 beats/min in a patient who does not have a
permanent pacemaker;
5. second- or third-degree heart block without a permanent
pacemaker;
6. active peptic ulcer disease or gastrointestinal bleeding within
previous 6 wk;
7. intracranial hemorrhage in the 6 mo prior to randomization;
8. subarachnoid hemorrhage or epidural hematoma unless the
event occurred N6 mo prior to randomization and the
offending aneurysm or arterial lesion has been repaired;
9. drug-eluting coronary stent b1 y prior to randomization;
10. bare-metal coronary stent b6 wk prior to randomization;
11. P2Y12 inhibitor within 72 h prior to surgery or intent to start during
the first 7 d after surgery; or currently taking an α-2 agonist,
α-methyldopa, monoamine oxidase inhibitors, or reserpine;
12. planned use of therapeutic dose anticoagulation during the first
3 d after surgery;
13. undergoing intracranial surgery, carotid endarterectomy, or
retinal surgery;
14. not consenting to participate in POISE-2 prior to surgery; or
15. previously enrolled in the POISE-2 trial.
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June 2014rates.When clinically important hypotension or bradycardia
persists, or the patient requires ongoing inotrope or
vasopressor administration, study personnel encourage
removal of the clonidine patch.
For patients experiencing a life-threatening or major
bleed, study personnel recommend that patients have their
ASA trialmedication held until the bleeding is stabilized and
the attending physician believes it is safe to restart the ASA
trial medication. Medical management, including any drug
therapy, is at the discretion of the attending physician.
Patient follow-up
Patients have a troponinmeasurement (or creatine kinase–
myocardial band if troponin is not available) drawn 6 to 12
hours after surgery and on the first, second, and third days
after surgery. Patients have electrocardiography (ECG)
immediately after an elevated troponin is detected. Research
personnel follow up patients throughout their hospital stay
andcontact patients at 30days and1 year after randomization
to determine if a patient has experienced a trial outcome.
Trial outcomes
The overall primary outcome of the POISE-2 trial is a
composite of mortality and nonfatal myocardial infarction
at 30 days after randomization. The secondary outcome is
a composite of mortality, nonfatal myocardial infarction,
and nonfatal stroke at 30 days after randomization. Online
Appendix A reports the individual tertiary outcomes at 30
days after randomization.
In eachASA stratum and in the ASA group overall,wewill
also assess a composite outcome of mortality, nonfatalmyocardial infarction, cardiac revascularization procedure,
nonfatal pulmonary embolism, and nonfatal deep venous
thrombosis at 30 days after randomization. The safety
outcomes for ASA are stroke, clinically important hypoten-
sion, congestive heart failure, life-threatening bleeding, and
major bleeding at 30 days after randomization. The safety
outcomes for clonidine are stroke, clinically important
hypotension, clinically important bradycardia, and conges-
tive heart failure at 30 days after randomization.
For the 1-year follow-up, our primary outcome is
mortality and nonfatal myocardial infarction. Online
Appendix A reports the 1-year secondary outcomes.
Online Appendix B provides definitions for all outcomes.
Outcome adjudication
Outcome adjudicators, who are blinded to treatment
allocation, are adjudicating the following outcomes:
death (vascular vs nonvascular), myocardial infarction,
nonfatal cardiac arrest, pulmonary embolism, deep
venous thrombosis, stroke, life-threatening bleeding,
major bleeding, and peripheral arterial thrombosis. We
will use the decisions of the outcome adjudicators for all
statistical analyses.
Statistical considerations
Sample size. Weassumed that each of clonidine andASA
will result in a hazard ratio (HR) of 0.75 for the primary
outcome (mortality or nonfatal myocardial infarction). We
used the control event rate for mortality and nonfatal
myocardial infarction in POISE and adjusted this event rate
accounting for the factorial design, and this suggests aplacebo
event rate of 6.1%. POISE-2 will include 10,000 patients
because this will provide 84% power if our event rate is 6.1%
and 81% power if our event rate is 5.6% (2-sided α = .05).
Data analysis
We will analyze patients in the treatment group to
which they are allocated, according to the intention-to-
treat principle. We will compare patients allocated to
clonidine with patients allocated to clonidine placebo,
and we will compare patients allocated to ASA with
patients allocated to ASA placebo.
Main analysis. We will present the time-to-the first
occurrence of one of the components of the primary
outcome using the Kaplan-Meier estimator. We will use Cox
proportional hazards models to estimate the effect of each
individual study drug on the HR for the primary and
secondary outcomes, with stratification according to wheth-
er treatment included the other agent. We will calculate the
HRs and their associated 95% CIs. We will infer statistical
significance if the computed 2-sided P value is b.05. We
anticipate that the treatment effect of clonidine and ASA, if
present, will act independently; wewill, however, evaluate
the possibility of synergism or antagonism by formally
testing the interaction term in a Cox model.
Table III. Baseline characteristics (n = 7500)
ge (y), mean (SD) 68.2 (10.4)
ender (female) 46.6%
rerandomization heart rate (beats/min), mean (SD) 76.4 (12.6)
rerandomization systolic blood pressure (mm Hg),
mean (SD)
141.1 (20.0)
ercentage of patients fulfilling eligibility criterion
History of coronary artery disease 23.5
History of peripheral arterial disease 9.1
History of stroke 5.5
History of vascular disease (ie, any of above) 34.0
Undergoing major vascular surgery 5.5
3 of 9 risk criteria 82.1
Undergoing major surgery 76.9
History of congestive heart failure 3.7
History of a transient ischemic attack 3.8
Diabetes and currently on an oral hypoglycemic
agent or insulin
38.3
Age ≥70 y 50.4
Hypertension 86.0
Preoperative serum creatinine N175 μmol/L
(N2.0 mg/dL)
3.4
History of smoking within 2 y of surgery 25.7
Emergent/Urgent surgery 7.3
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Volume 167, Number 6Subgroup analyses. Cox proportional hazards
models assessing the primary outcome will provide the
basis for evaluating the clonidine subgroup analyses (ie,
neuraxial blockade, vascular surgery, β-blocker usage in
the 24 hours preceding surgery, and baseline risk
according to the revised cardiac risk index)26 and the
ASA subgroup analyses (ie, ASA stratum and baseline risk
according to the revised cardiac risk index). We will infer
a subgroup effect if the interaction term of treatment and
subgroup is statistically significant at P b .05.
Interim analyses. Three interim efficacy analyses based
on the primary outcome occurred when 25%, 50%, and 75%
of the 30-day data were available. The External Safety and
Efficacy and Monitoring Committee (ESEMC) used the
modified Haybittle-Peto rule of 4 SDs (α = .0001) for analyses
in the first half of the trial and3SDs (α= .00047) for all analyses
in the second half.27,28 For a finding of 1 or both active
treatments to be considered significant, these predefined
boundaries had to be exceeded in at least 2 consecutive
analyses, 3 or more months apart. The α level for the final
analysis will remain the conventional α = .05, given the
infrequent interim analyses, their extremely low α levels, and
the requirement for confirmation with subsequent analyses.
The ESEMCmonitored for an adverse impact of clonidine
on stroke or mortality and ASA on stroke, life-threatening
bleeding, or mortality. For these analyses, a 3-SD excess in
the first half and a 2.6-SD excess in the secondhalf of the trial
would have triggered discussions about stopping for harm.
Trial organization
The Population Health Research Institute is the coordinat-
ing center for this study worldwide and is primarily
responsible for the organization of the trial, development of
the randomization scheme, the study database, data consis-
tency checks, data analysis, and coordination of the study
centers. The trial structure includes the following groups: the
ProjectOfficeOperationsCommittee,National Coordinators,
Investigators, Coordinating Center, International Operations
Committee, Steering Committee, Adjudication Committee,
and the ESEMC.Online Appendix C lists the groupmembers.
Current status of the trial and funding
The POISE-2 trial is currently recruiting patients in 135
centers within 23 countries and has randomizedmore than
9,000 patients as of October 2013. Tables III and IV present
baseline characteristics and type of surgery and anesthesia/
analgesia, respectively. These data demonstrate that among
the first 7,500 patient randomized, patients' mean age was
68.2 years, 53.4% were male, 34.0% had a history of
vascular disease, and 38.3% were treated for diabetes.
Participants underwent orthopedic (38.1%), general
(27.0%), urologic or gynecologic (17.2%), vascular (6.6%),
thoracic (5.7%), or other (5.4%) surgery; 23.9% of the
patients received a β-blocker within 24 hours preceding
surgery, and 56.8%of patients received a general anesthesiaA
G
P
P
Pand 43.2% received neuraxial anesthesia or a nerve block.
After the 3 interim analyses, the ESEMC was unanimous in
recommending that the POISE-2 trial continue.
Grants from the Canadian Institutes of Health Research,
the Commonwealth Government of Australia's National
Health and Medical Research Council, and the Spanish
Ministry of Health and Social Policy fund POISE-2.
Boehringer Ingelheim provided the clonidine study drug
and some funding, and Bayer Pharma AG provided the ASA
study drug. The authors are solely responsible for the design
and conduct of this trial, all trial analyses, the drafting and
editing of the manuscript, and its final contents.Discussion
Patients undergoing noncardiac surgery frequently expe-
rience major perioperative vascular complications. There
exists encouraging but inconclusive evidence that clonidine
and ASA may prevent perioperative cardiovascular events.
Oral clonidine is absorbed rapidly and reaches peak
serum concentrations within 2 to 4 hours and demon-
strates physiological effects within 1 hour; these effects
persist for 24 hours.29 Transdermal clonidine reaches
peak serum concentrations at 48 hours after application
and demonstrates physiological effects at 24 hours; after
removal of the clonidine patch serum concentrations,
physiological effects can persist for 2 to 3 days.30
Administering oral clonidine 2 to 4 hours before surgery
allows us to achieve physiological effects before surgery,
and these effects will persist for 24 hours. Applying the
transdermal patch 2 to 4 hours before surgery allows us to
achieve physiological effects starting around the time the
effects of the oral clonidine dose are resolving. This
Table IV. Type of surgery and anesthesia/analgesia (n = 7500)
Percentage of patients
Type of surgery
Orthopedic 38.1
General 27.0
Urologic or gynecologic 17.2
Vascular 6.6
Thoracic 5.7
Other 5.4
Type of anesthesia/analgesia
General 46.6
Neuraxial anesthesia
Lumbar epidural 1.8
Spinal 25.3
Combined spinal epidural 1.8
General and epidural anesthesia
General and thoracic epidural 5.3
General and lumbar epidural 1.1
Nerve block 0.7
General and nerve block 3.8
Spinal and nerve block 4.4
Other combinations 9.2
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regimen (ie, an effective dose b0.3 mg/d).14
Multivariable analyses suggested that clinically important
hypotensionmayhave caused the increased risk of death and
stroke with metoprolol in POISE.4 Perioperative clonidine
may result in clinically important hypotension, so we have
incorporated several design features to minimize this risk. In
POISE-2, patients must have a systolic blood pressure ≥105
mm Hg and a heart rate≥55 beats/min to be eligible for the
trial and to receive the clonidine study drug, whereas in
POISE, patients received the study drug if they had a systolic
blood pressure ≥100 mm Hg and their heart rate was ≥50
beats/min. We have also incorporated more frequent
monitoring of blood pressure and heart rate in POISE-2 (ie,
prior to study drug administration, 1 hour after administra-
tion, and every 4 hours for the first 96 hours after surgery)
compared with POISE (in which blood pressure was only
monitored prior to and during metoprolol administration).
Our decision to evaluate low-dose ASA was based on the
following. The only surgical trial that has compared low vs
high-dose ASA randomized patients undergoing carotid
endarterectomy to low-dose ASA (ie, 709 patients assigned
81mg/d and 708 patients assigned 325mg/d), and they had
a lower risk (ie, 6.2%) of the primary outcome (ie, a
composite of death, nonfatal myocardial infarction, and
nonfatal stroke at 3 months) than the patients randomized
to high-dose ASA (ie, 715 patients assigned 650 mg/d and
717 patients assigned 1,300 mg/d), of whom 8.4%
experienced the primary outcome (P = .03).31
The CURRENT OASIS-7 trial evaluated 2 doses of ASA.
This trial randomized 25,087 patients with acute coro-
nary syndrome to ASA 75 to 100 mg/d vs ASA 300 to
325 mg/d. At 30-day follow-up, there was no difference
between the groups regarding major cardiovascularoutcomes.32 The Antithrombotic Trialists' Collaboration
meta-analysis of RCTs evaluating the effects of initiating
antiplatelet therapy demonstrated that low-dose ASA (75-
150 mg daily) was as effective but less gastrotoxic than
higher doses;19 however, in acute settings, an initial
loading dose of 160 mg of ASA (which is sufficient to
provide rapid and complete inhibition of thromboxane
A2–mediated platelet aggregation)
33 may be required.34
Our decision to allow patients to participate in the
Continuation Stratum even if they have taken their ASA no
less than 72 hours prior to surgery was based upon the
following 2 considerations. First, the mean life span of
human platelets is approximately 8 to 10 days, and
about 12% of circulating platelets are replaced every 24
hours.35,36 O'Brien36 demonstrated that abnormal platelet
aggregation after ingestion of ASA can be corrected ex
vivo by 10% normal platelet-rich plasma. Furthermore, it
has been reported that if as little as 20% of platelets have
normal COX-1 activity, hemostasis is unimpaired.37,38
Therefore, stopping ASA for 72 hours is likely to ensure
substantial (if not complete) recovery of platelet func-
tion. Second, investigators of the ISIS-2 trial that
randomized 17,187 patients to ASA or placebo in the
acute myocardial infarction setting included patients who
were taking ASA chronically even if they took ASA on the
day of their myocardial infarction.34 There were 2,266
patients in this subgroup, and ASA demonstrated a
statistically significant reduction in vascular death,
consistent with the overall finding.34
POISE-2 is a large factorial RCT designed to determine if
clonidine, and separately if ASA, can prevent mortality and
nonfatal myocardial infarction at 30 days of follow-up. To
date, the POISE-2 trial has randomized more than 9,000
patients. POISE-2 will answer 2 crucial management
questions and influence future perioperative practices
around the world.
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at30daysandsecondary1-yearoutcomes
Individual tertiary outcomes at 30 days after randomiza-
tion include: total mortality, vascular mortality, myocardial
infarction, nonfatal cardiac arrest, cardiac revascularization
procedure, pulmonary embolism, deep venous thrombo-
sis, new clinically important atrial fibrillation, amputation,
peripheral arterial thrombosis, infection, sepsis, rehospita-
lization for vascular reasons, length of hospital stay, length
of intensive care unit/cardiac care unit stay, and new acute
renal failure requiring dialysis.A secondary outcome includes the composite of
mortality, nonfatal myocardial infarction, and nonfatal
stroke at 1 year after randomization. Individual second-
ary 1-year follow-up outcomes include all-cause mortal-
ity, vascular mortality, myocardial infarction, nonfatal
cardiac arrest, cardiac revascularization procedure,
stroke, pulmonary embolism, deep venous thrombo-
sis, amputation, peripheral arterial thrombosis, new
diagnosis of cancer, diagnosis of recurrent cancer,
rehospitalization for vascular reason, and chronic
incisional pain. Online Appendix B provides defini-
tions for all outcomes.
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Sub classification of death Judicial outcome assessors will classify all deaths as either vascular or nonvascular. Vascular death is defined as any death
with a vascular cause and includes those deaths after a myocardial infarction, cardiac arrest, stroke, cardiac
revascularization procedure (ie, percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery),
pulmonary embolus, hemorrhage, or deaths due to an unknown cause. Nonvascular death is defined as any death due to a
clearly documented nonvascular cause (eg, trauma, infection, malignancy).Myocardial infarction The diagnosis of myocardial infarction requires any one of the following criterion:
1. A typical rise of troponin or a typical fall of an elevated troponin detected at its peak post surgery in a patient without a
documented alternative explanation for an elevated troponin (eg, pulmonary embolism) OR a rapid rise and fall of creatine
kinase–myocardial band. This criterion also requires that 1 of the following must also exist:
A. ischemic signs or symptoms (ie, chest, arm, neck, or jaw discomfort; shortness of breath, pulmonary edema);
B. development of pathologic Q waves present in any 2 contiguous leads that are ≥30 ms;
C. ECG changes indicative of ischemia (ie, ST segment elevation [≥2 mm in leads V1, V2, or V3 OR ≥1 mm in the other
leads], ST segment depression [≥1 mm], or symmetric inversion of T waves ≥1 mm) in at least 2 contiguous leads;
D. coronary artery intervention (ie, PCI or CABG surgery); or
E. new or presumed new cardiac wall motion abnormality on echocardiography or new or presumed new fixed defect on
radionuclide imaging
2. Pathologic findings of an acute or healing myocardial infarction; or
3. Development of new pathological Q waves on an ECG if troponin levels were not obtained or were obtained at times that
could have missed the clinical eventNonfatal cardiac arrest Nonfatal cardiac arrest is defined as successful resuscitation from either documented or presumed ventricular fibrillation,
sustained ventricular tachycardia, asystole, or pulseless electrical activity requiring cardiopulmonary resuscitation,
pharmacological therapy, or cardiac defibrillation.Cardiac revascularization
procedureCardiac revascularization procedure is defined as PCI or CABG surgery.Stroke Stroke is defined as a new focal neurologic deficit thought to be vascular in origin with signs or symptoms lasting more than
24 hours or leading to death.Pulmonary embolism The diagnosis of pulmonary embolism requires any one of the following:
1. A high probability ventilation/perfusion lung scan;
2. An intraluminal filling defect of segmental or larger artery on a helical computed tomographic scan;
3. An intraluminal filling defect on pulmonary angiography; or
4. A positive diagnostic test for deep venous thrombosis (eg, positive compression ultrasound) and one of the following:
A. nondiagnostic (ie, low or intermediate probability) ventilation/perfusion lung scan; or
B. nondiagnostic (ie, subsegmental defects or technically inadequate study) helical computed tomographic scan.Deep venous thrombosis
of leg or armThe diagnosis of deep venous thrombosis requires any one of the following:
1. A persistent intraluminal filling defect on contrast venography;
2. Noncompressibility of one or more venous segments on B mode compression ultrasonography; or
3. A clearly defined intraluminal filling defect on contrast enhanced computed tomography.New clinically important
atrial fibrillationNew clinically important atrial fibrillation is defined as new atrial fibrillation that results in angina, congestive heart failure,
symptomatic hypotension, or that requires treatment with a rate controlling drug, antiarrhythmic drug, or electrical
cardioversion.Rehospitalization for
vascular reasonsRehospitalization for vascular reasons is defined as rehospitalization for myocardial infarction, cardiac arrest, stroke,
congestive heart failure, ischemic symptoms with ST or T wave changes on an ECG, cardiac arrhythmia, cardiac
revascularization procedure, deep venous thrombosis, pulmonary embolus, any vascular surgery, or bleeding.Life-threatening bleeding Life-threatening bleeding is bleeding that is fatal, or leads to significant hypotension that requires inotrope or vasopressor
therapy, urgent (within 24 hours) surgery (other than superficial vascular repair), or intracranial hemorrhage.Major bleeding Major bleeding is defined as bleeding that is not specified under “life-threatening bleeding” above and results in any one of
the following:
1. a hemoglobin level ≤70 g/L and the patient receives a transfusion of ≥2 units of red blood cells;
2. a hemoglobin drop of ≥50 g/L and the patient receives a transfusion of ≥2 units of red blood cells;
3. the patient receives a transfusion of ≥4 units of red blood cells within a 24-h period;
4. any one of the following interventions (ie, embolization, superficial vascular repair, nasal packing); or
5. retroperitoneal, intraspinal, or intraocular (confirmed clinically or on imaging) bleeding.
(continued )
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hypotensionClinically important hypotension is defined as a systolic blood pressure b90 mm Hg requiring fluid resuscitation, intra-aortic
balloon pump, an inotropic or vasopressor agent, or study drug discontinuation.Clinically important
bradycardiaClinically important bradycardia is defined as a heart rate b55 beats/min requiring a temporary pacemaker,
sympathomimetic agent, atropine, or study drug discontinuation.Congestive heart failure The definition of congestive heart failure requires at least one of the following clinical signs (ie, any of the following signs:
elevated jugular venous pressure, respiratory rales/crackles, crepitations, or presence of S3) and at least one of the following
radiographic findings (ie, vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema).New acute renal failure
requiring dialysisDialysis is defined as the use of a hemodialysis machine or peritoneal dialysis apparatus.Amputation Amputation is defined as an amputation procedure subsequent to the initial surgery.Peripheral arterial
thrombosisWe will consider a peripheral arterial thrombosis to have occurred where there is clear evidence of abrupt occlusion of a
peripheral artery (ie, not a stroke, myocardial infarction, or pulmonary embolism) consistent with either an acute local
thrombotic event or a peripheral arterial embolism. To fulfill this definition, we require at least one of the following objective
findings of peripheral arterial thrombosis:
1. Surgical report indicating evidence of arterial thrombosis/peripheral arterial embolism;
2. Pathological specimen demonstrating arterial thrombosis/peripheral arterial embolism;
3. Imaging evidence consistent with arterial thrombosis/peripheral arterial embolism; or
4. Autopsy reports documenting arterial thrombosis/peripheral arterial embolism.Infection/sepsis Infection is defined as a pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by
pathogenic or potentially pathogenic organisms. Sepsis is a clinical syndrome defined by the presence of both infection and a
systemic inflammatory response. Systemic inflammatory response requires 2 or more of the following factors: core
temperature N38°C or b36°C; heart rate N90 beats/min; respiratory rate N20 breaths/min; white blood cell count N12 ×
109/L or b4 × 109 L.New diagnosis of cancer
since surgeryDefined as a patient with a new diagnosis of cancer (ie, the patient has no prior history of this cancer) within the first 12 mo
after their initial surgery for which they were enrolled in POISE-2. This outcome is for all cancers except nonmelanoma skin
cancers.Diagnosis of recurrent
cancer since surgeryDefined as patients with any diagnosis of recurrent cancer (ie, a recurrence of a previous cancer for which the patient
received curative treatment) within the 12 mo after their initial surgery for which they were enrolled in POISE-2. Recurrent
cancer does not include nonmelanoma skin cancers.Appendix C. Trial groups
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